Illumina Accelerator is the investment arm of Illumina funding early stage genomics companies. They offer early stage companies financial support, mentorship and access to genomic technologies such as sequencing systems, reagents, and lab space.
The Illumina Accelerator runs 2 six month funding cycles each year consisting of up to 5 companies per cycle with access to up to $100,000 in convertible notes from seed investors and a $20,000 unsecured line of credit. Chosen companies agree to give Illumina Accelerator 8% of common stock for participating in their accelerator program.
During each six month funding cycle selected companies are actively coached by mentors at the Illumina Accelerator to develop a custom curriculum for company building, business strategy, technology development, and pitch development. Credits are given to each company for access to Illumina sequencing technologies, and companies can hire scientists at illumina to help with experimental design. At the end of each funding cycle companies meet with venture capitalists affiliated with the Illumina Accelerator to pitch their business ideas and technologies.
Companies also have the opportunity to receive funding from a $40 million dollar pool of funding from the Illumina Accelerator Boost Capital fund. Illumina Accelerator Boost Capital has a deal with Viking Global Investors to match funding dollar-for-dollar for startups managing to raise in between $1 million and $5 million in funding.
Illumina Accelerator's grant competition encourages entrepreneurs to create companies using next generation sequencing technologies. Grant winners are able to spend one week running sequencing experiments for proof-of-concept at Illumina Accelerator. When the grant is awarded it needs to be used within 6-months. The grant also gives entrepreneurs one business coaching session, and two sequencing experiment design meetings with a senior scientist at Illumina.
On August 17, 2017 Illumina Accelerator announced they will collaborating with a personal genomics company called Helix. The partnership seeks to help entrepreneurs develop DNA-driven products and services. Startups accepted into Illumina Accelerator's accelerator program will gain access to Helix's expertise and sequencing platform. The co-founder and senior vice president of Helix, Justin Kao, had the following to say about the partnership "We are proud to collaborate with Illumina Accelerator to stimulate innovation in personal genomics by helping selected startups harness their creativity and build best-in-class DNA-powered products for everyday use".
Head of Illumina Accelerator & Co-Founder
Senior Vice President & General Counsel
Executive Vice President, Chief Administrative Officer, & Chief Financial Officer
Chief Technical Officer & Co-Founder
Executive Vice President. Operations, Products & Strategy
Chief Medical Officer & Interim General Manager
Senior Vice President & General Manager of Enterprise Informatics
$40 million genomics accelerator introduced by Helix and Illumina
Illumina Accelerator explores genomic innovation in Ontario - Ontario Genomics
Illumina Accelerator Frequently Asked Questions
The genomics-focused Illumina Accelerator backs five new companies
Documentaries, videos and podcasts
- AgricultureCultivation of life forms for food, fiber, biofuel and other products used to sustain life
- GeneticsScience of genes, heredity, and variation in living organisms
- HealthcareDiagnosis, treatment and prevention of disease, illness, and injury
- Illumina VenturesIllumina Ventures is a venture capital firm focused on early-stage companies developing applications of genomics. It invests in therapeutics, life science tools, and clinical diagnostics.
- GenomicsThe study of genomes. A genome is the full set of genetic material from an organism. Genomics is an area of research that is concerned with all genes and other functional DNA elements within an organism and how they control the development and life of that organism.
- Show More